PortfoliosLab logo
Biotech-2023
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Diversification

Asset Allocation


Performance

Performance Chart


Loading data...

The earliest data available for this chart is Apr 24, 2019, corresponding to the inception date of MREO

Returns By Period


YTD1M6M1Y5Y*10Y*
^GSPC
S&P 500
-3.77%7.44%-5.60%8.37%14.12%10.46%
Biotech-2023-4.34%10.05%-15.42%-10.25%6.42%N/A
ARWR
Arrowhead Pharmaceuticals, Inc.
-30.69%17.28%-40.48%-40.99%-18.58%7.78%
SAGE
Sage Therapeutics, Inc.
20.81%-5.07%3.96%-44.87%-30.19%-19.53%
TGTX
TG Therapeutics, Inc.
11.76%-6.50%16.77%102.41%10.75%7.99%
MREO
Mereo BioPharma Group plc
-31.14%31.69%-43.43%-20.46%14.08%N/A
ONCT
Oncternal Therapeutics, Inc.
0.00%0.00%-58.54%-93.56%-59.89%-54.23%
NTLA
Intellia Therapeutics, Inc.
-30.36%19.94%-51.46%-66.80%-12.27%N/A
DTIL
Precision BioSciences, Inc.
34.65%21.28%-38.78%-51.79%-53.35%N/A
ISRG
Intuitive Surgical, Inc.
2.79%9.60%0.01%38.74%24.54%25.57%
*Annualized

Monthly Returns

The table below presents the monthly returns of Biotech-2023, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20257.73%-2.67%-10.10%7.19%-5.33%-4.34%
202410.61%1.89%-7.31%-14.41%4.96%6.47%5.05%-2.15%-9.40%-3.05%9.25%-12.85%-14.08%
20235.11%-5.43%-5.41%27.66%-2.29%6.21%-6.68%-16.14%-6.91%-3.59%11.80%18.51%15.93%
2022-20.37%-5.23%-4.34%-21.44%-8.77%5.43%16.26%-1.95%-11.54%12.56%4.68%4.97%-31.96%
2021-3.92%3.82%-1.52%6.40%-5.28%14.53%-8.86%3.38%-5.51%0.06%-10.10%3.35%-6.14%
2020-15.08%-8.40%-17.86%15.36%8.88%23.45%5.55%7.50%0.24%7.39%16.81%28.37%81.46%
2019-2.71%-0.81%9.50%-1.59%3.81%-8.59%10.15%31.77%-7.06%33.10%

Expense Ratio

Biotech-2023 has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.


The portfolio doesn't include any funds that charge management fees.

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of Biotech-2023 is 2, meaning it’s performing worse than 98% of other portfolios on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of Biotech-2023 is 22
Overall Rank
The Sharpe Ratio Rank of Biotech-2023 is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of Biotech-2023 is 22
Sortino Ratio Rank
The Omega Ratio Rank of Biotech-2023 is 22
Omega Ratio Rank
The Calmar Ratio Rank of Biotech-2023 is 22
Calmar Ratio Rank
The Martin Ratio Rank of Biotech-2023 is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Portfolio components
Sharpe ratioSortino ratioOmega ratioCalmar ratioMartin ratio
ARWR
Arrowhead Pharmaceuticals, Inc.
-0.71-0.950.89-0.54-1.45
SAGE
Sage Therapeutics, Inc.
-0.65-0.850.89-0.51-1.20
TGTX
TG Therapeutics, Inc.
1.572.281.281.359.96
MREO
Mereo BioPharma Group plc
-0.42-0.050.99-0.27-0.67
ONCT
Oncternal Therapeutics, Inc.
-0.85-2.190.57-0.94-1.22
NTLA
Intellia Therapeutics, Inc.
-0.93-1.470.83-0.68-1.44
DTIL
Precision BioSciences, Inc.
-0.70-0.890.90-0.52-1.12
ISRG
Intuitive Surgical, Inc.
1.171.811.251.464.64

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Biotech-2023 Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: -0.40
  • 5-Year: 0.19
  • All Time: 0.16

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 0.41 to 0.94, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of Biotech-2023 compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend yield


Biotech-2023 doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Biotech-2023. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biotech-2023 was 62.53%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current Biotech-2023 drawdown is 47.33%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-62.53%Jul 2, 2021217May 11, 2022
-51.27%Dec 2, 201974Mar 18, 202084Jul 17, 2020158
-18.21%Jan 15, 202135Mar 8, 202167Jun 11, 2021102
-15.2%Aug 22, 201929Oct 2, 201922Nov 1, 201951
-9.51%Sep 3, 20203Sep 8, 20206Sep 16, 20209

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Diversification

Diversification Metrics


Number of Effective Assets

The portfolio contains 8 assets, with an effective number of assets of 5.13, reflecting the diversification based on asset allocation. This number of effective assets indicates a moderate level of diversification, where some assets may have a more significant influence on overall performance.

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

^GSPCONCTMREODTILISRGSAGETGTXARWRNTLAPortfolio
^GSPC1.000.200.240.330.720.380.430.440.480.62
ONCT0.201.000.190.200.160.250.220.230.220.36
MREO0.240.191.000.210.190.250.230.300.270.51
DTIL0.330.200.211.000.260.340.370.370.440.48
ISRG0.720.160.190.261.000.310.380.370.400.62
SAGE0.380.250.250.340.311.000.430.450.460.64
TGTX0.430.220.230.370.380.431.000.490.520.68
ARWR0.440.230.300.370.370.450.491.000.560.78
NTLA0.480.220.270.440.400.460.520.561.000.73
Portfolio0.620.360.510.480.620.640.680.780.731.00
The correlation results are calculated based on daily price changes starting from Apr 25, 2019